TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19118956
Drug: Dietary intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary intervention group (DG) receiving approximately 1200 mg of calcium and 7.5 microg of vitamin D3 per day via fortified dairy products and attending biweekly dietary and lifestyle intervention sessions
Study: 3618443
Drug: Initial oral
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial oral provocation tests (OPT)
Study: 31409486
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + Bevacizumab (BEV)
Study: 31409486
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + Placebo (P)
Study: 31409486
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (BEV and placebo)
Study: 23025500
Drug: Positive stereotype
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive stereotype exposure (e.g., 'Asians are good at math', 'women are nurturing')
Study: 16904542
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) without AVJ ablation
Study: 26114393
Drug: N-Acetylcysteine added
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-Acetylcysteine added to University of Wisconsin solution
Study: 26114393
Drug: Standard University
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard University of Wisconsin solution
Study: 16749411
Drug: Active pulsed
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active pulsed electromagnetic therapy (PEMT)
Study: 15090561
Drug: Clozapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (mean dosage 35.8 mg)
Study: 10886488
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 mg) suppression test
Study: 7930246
Drug: Prourokinase (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prourokinase (60 mg or 80 mg monotherapy or 60 mg primed with 250,000 IU recombinant urokinase)
Study: 31689482
Drug: Loxoprofen sodium
Normalized name: loxoprofen sodium dihydrate
DrugBank: Loxoprofen (DB09212)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Loxoprofen sodium (60 mg once orally)
Study: 26634113
Drug: Placebo mouth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo mouth wash (15 ml)
Study: 19092152
Drug: Alfuzosin 10
Normalized name: Alfuzosin 10mg Oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 10 mg per day for 12 weeks
Study: 15949728
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) at doses of 0.05, 0.2, and 0.5 microg/kg/min
Study: 15949728
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide (NO) at doses of 40, 60, and 80 ppm
Study: 7995764
Drug: Conformal radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conformal radiation treatment
Study: 7995764
Drug: Standard radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard radiation treatment
Study: 29597305
Drug: Alcohol with
Normalized name: GNP 70% Isopropyl Alcohol with Wintergreen Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol with carbohydrate (25 g sucrose)
Study: 29597305
Drug: Alcohol consumption
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol consumption (20 g for males; 10 g for females)
Study: 12544674
Drug: Constant‐estrogen, intermittent‐progestogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant‐estrogen, intermittent‐progestogen hormone replacement regimen (Ortho‐Prefest)
Study: 11018622
Drug: Melanotan II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melanotan II (0.025 mg/kg)
Study: 31091064
Drug: PRIMER protocol
Normalized name: Primor
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRIMER protocol (intrauterine PRP injection and subcutaneous G-CSF injection)
Study: 31091064
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (first IVF/ICSI attempt without PRP or G-CSF injection)
Study: 30030584
Drug: GLIF combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLIF combination chemotherapy (gemcitabine 800 mg/m2, levofolinate 100 mg/m2, irinotecan 80 mg/m2, 5-FU 1000 mg/m2)
Study: 7782272
Drug: Phenelzine (monamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenelzine (monamine oxidase inhibitor)
Study: 7782272
Drug: Brofaromine (reversible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brofaromine (reversible monamine oxidase inhibitor)
Study: 7782272
Drug: Moclobemide (reversible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (reversible monamine oxidase inhibitor)
Study: 7782272
Drug: Fluvoxamine (serotonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (serotonin selective reuptake inhibitor)
Study: 7782272
Drug: Sertraline (serotonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (serotonin selective reuptake inhibitor)
Study: 31881181
Drug: ADVIA Centaur®
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADVIA Centaur® XP system for insulin determination
Study: 31881181
Drug: Insulin assay
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin assay applied in bioequivalence study of miglitol
Study: 28276638
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 5 mg/year
Study: 26828618
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 5 mg
Study: 22305183
Drug: Oral acetylcysteine
Normalized name: Acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acetylcysteine (1200 mg twice daily for 2 days, starting the day before contrast exposure)
Study: 15767218
Drug: Valproate MR
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate MR granules administered once/day or twice/day (500 mg)
Study: 15767218
Drug: Valproate MR
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate MR granules administered with yogurt or after a high-fat meal
Study: 15767218
Drug: Existing valproate
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Existing valproate SR formulations
Study: 12410497
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) orally (600 mg) plus saline every 12 hr for 24 hr before and after the procedure
Study: 12410497
Drug: Saline (0.45%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.45% normal saline at 1 cc/kg) for 12 hr before and 12 hr after the procedure
Study: 10519498
Drug: Lidocaine with
Normalized name: Lidocaine with Tegaderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine with epinephrine (2.5 microg/ml)
Study: 6127901
Drug: Prenalterol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenalterol (20 mg in controlled release preparation)
Study: 6127901
Drug: Prenalterol (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenalterol (intravenous dose)
Study: 6127901
Drug: Prenalterol (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenalterol (oral dose)
Study: 29346837
Drug: Ertugliflozin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin (100 mg; supratherapeutic dose)
Study: 29346837
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg; positive control)
Study: 22246026
Drug: CGRP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CGRP infusion (1.5 μg/min for 20 min)
Study: 19439741
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide plus doxorubicin)
Study: 15532079
Drug: Dornase alpha
Normalized name: Dornase alpha
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dornase alpha (2.5 mg daily)
Study: 9772947
Drug: Daflon 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daflon 500 mg (2 tablets)
Study: 8205595
Drug: Lansoprazole and
Normalized name: Lansoprazole and naproxen only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole and amoxicillin
Study: 364059
Drug: Doxycycline administered
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline administered before and during the first three postoperative days
Study: 26757466
Drug: Nitinol coils
Normalized name: BOIL-EASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitinol coils treatment
Study: 20642548
Drug: febuxostat 80
Normalized name: febuxostat 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: febuxostat 80 mg + hydrochlorothiazide 50 mg
Study: 12058515
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy for cognitive-perceptual abilities
Study: 12058515
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy for motor capacities
Study: 12164890
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplementation during hemodialysis
Study: 9854466
Drug: 5-hydroxytryptamine (serotonin)
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-hydroxytryptamine (serotonin) infusion at increasing doses (15 nmol.min-1.kg-1 and 60 nmol.min-1.kg-1)
Study: 406103
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (betamethasone valerate and sodium cromoglycate)
Study: 26479132
Drug: Daily monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily monitoring condition (n = 89)
Study: 26479132
Drug: Daily report
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily report total cigarettes
Study: 9466512
Drug: Candid 1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candid 1, a live attenuated Junin virus vaccine
Study: 365797
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid (CDCA), 200 mg/day for 5 days
Study: 31670004
Drug: Standard PAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard PAP treatment (SG)
Study: 31670004
Drug: Proactive telemonitored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive telemonitored PAP treatment (TG)
Study: 28480505
Drug: Cardamom supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardamom supplementation (3 g d-1) for 8 weeks
Study: 22835761
Drug: Enzyme-inducing antiepileptic
Normalized name: lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enzyme-inducing antiepileptic drugs (EI-AEDs)
Study: 21189395
Drug: Anthracycline-containing chemotherapy
Normalized name: methacycline
DrugBank: Metacycline (DB00931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anthracycline-containing chemotherapy
Study: 31916660
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of prolonged exposure and sertraline
Study: 25509730
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of loratadine and nasal spray of budesonide
Study: 8736270
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy (2.0 IU/m2 per day)
Study: 1704985
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nitrendipine and cilazapril
Study: 23953493
Drug: Milnacipran (≥100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran (≥100 mg/day)
Study: 21421726
Drug: SB-773812 100
Normalized name: SB-773812
DrugBank: SB-773812 (DB16042)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-773812 100 mg/d
Study: 15534128
Drug: 2% pirenzepine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% pirenzepine ophthalmic gel
Study: 29566659
Drug: Low-dose, high-frequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose, high-frequency (LDHF) training approach
Study: 28270187
Drug: HICS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HICS treatment
Study: 16520570
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg of ketamine administered after induction of anesthesia, approximately 5 min prior to surgery
Study: 16520570
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg of ketamine
Study: 12697866
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human keratinocyte growth factor (KGF) at doses of 60 and 80 microg/kg/d
Study: 11063766
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg orally, 3 times a day) during gentamicin therapy
Study: 30837403
Drug: Hot-etching solution
Normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hot-etching solution (Group C)
Study: 30837403
Drug: Non-treatment zirconia
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment zirconia (Group D)
Study: 30837403
Drug: Non-treatment nickel-chromium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment nickel-chromium alloy (Group E)
Study: 22023910
Drug: Experimental food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental food preparers attended 8 weekly interactive lessons
Study: 22023910
Drug: Control food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control food preparers received 8 weekly mailings with similar recipes and handouts
Study: 9101094
Drug: Continuous dobutamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous dobutamine infusion (6 micrograms/kg/min from 10 minutes before induction of anaesthesia till the fifth postoperative hour)
Study: 8942578
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no dobutamine infusion)
Study: 29843811
Drug: DCVax-L
Normalized name: DCVax-L
DrugBank: DCVax-L (DB17580)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCVax-L
Study: 23722616
Drug: QVA149 (indacaterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVA149 (indacaterol 110 μg/glycopyrronium 50 μg)
Study: 11565519
Drug: Irbesartan 300
Normalized name: irbesartan 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 300 mg daily
Study: 16505409
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 400 mg intramuscularly (single dose)
Study: 16505409
Drug: Venlafaxine 37.5
Normalized name: venlafaxine 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 37.5 mg per day for one week, then 75 mg per day
Study: 10871979
Drug: Slow titration
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow titration (every 6 weeks)
Study: 9201043
Drug: Dobutamine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine (5 to 200 micrograms/kg/min) administered to increase cardiac index and DO2 until all therapeutic goals were achieved.
Study: 9201043
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received dobutamine only if cardiac index was < 2.8 L/min/m2.
Study: 24904785
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg metoprolol on the day of surgery
Study: 28748625
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment arms combined
Study: 18580181
Drug: Lidocaine 1%
Normalized name: LIDOCAINE 1% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1% with a 1.5 mg/kg intravenous bolus in 10 min followed by a 1.5 mg . kg . h intravenous infusion
Study: 16086467
Drug: Conventional Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Medicine (CM) interventions
Study: 16086467
Drug: Complementary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary and Alternative Medicine (CAM) interventions
Study: 12461659
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of azathioprine and prednisone (NoCsA group, n=58)
Study: 23561637
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation at a dose of 1000 U/day for 12 months
Study: 21388579
Drug: Rivastigmine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine (3 mg twice a day, for 8 weeks)
Study: 21388579
Drug: Rehabilitation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation treatment only (No-RIV)
Study: 27702807
Drug: 1.25% fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25% fluoride gel
Study: 18663301
Drug: 0.5% fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% fluoride gel
Study: 9009677
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg bid for 14 days/amoxycillin 1000 mg bid for 14 days/tinidazole 500 mg bid for 14 days (Group A)
Study: 9009677
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg bid for 14 days/amoxycillin 1000 mg bid for 14 days (Group B)
Study: 9009677
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg bid for 14 days/azithromycin 500 mg/day for 3 days for 2 consecutive weeks (Group C)
Study: 10583349
Drug: Ondansetron 16
Normalized name: ondansetron 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 16 mg
Study: 6828338
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) 600 mg
Study: 19361739
Drug: Acetaminophen 600
Normalized name: acetaminophen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 600 mg
Study: 22392934
Drug: No neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No neoadjuvant therapy (Control)
Study: 21969009
Drug: Chlorthalidone (12.5-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (12.5-25 mg/d)
Study: 19158191
Drug: Spironolactone (50-75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (50-75 mg/d)
Study: 17229249
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus pioglitazone
Study: 9779521
Drug: Pergolide 0.25
Normalized name: pergolide 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pergolide 0.25 mg at bedtime
Study: 8018978
Drug: Nizatidine 150
Normalized name: nizatidine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 150 mg/day
Study: 7863254
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no regular treatment)
Study: 2511913
Drug: sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual nitroglycerin tablets
Study: 2511913
Drug: quickly dissolving
Approvals — FDA: no, EMA: no, PMDA: no
Description: quickly dissolving nitroglycerin compound
Study: 28301428
Drug: Adalimumab (ADA)
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab (ADA) treatment, open-label induction at weeks 0 and 2 by body weight (≥40 kg: 160 mg and 80 mg; <40 kg: 80 mg and 40 mg), followed by randomized double-blind dosing (high or low dose every other week) to week 52.
Study: 22136978
Drug: Amlodipine/losartan 5/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/losartan 5/50 mg fixed-dose combination
Study: 15277147
Drug: Fat plus
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat plus 50 g sodium caseinate
Study: 15277147
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fat, oligosaccharides, and casein
Study: 11382108
Drug: Early postoperative
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early postoperative oral feeding
Study: 2521699
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (3 mg/kg/wk)
Study: 124247
Drug: 1% spray
Normalized name: CLOTRIMAZOLE 1% SPRAY,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% spray solution
Study: 124247
Drug: 1% solution
Normalized name: GUMSOL 5%-0.01% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% solution
Study: 25487613
Drug: Droxidopa (100-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droxidopa (100-600 mg thrice-daily)
Study: 11699314
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.5% timolol plus 2% dorzolamide (n = 22)
Study: 31533578
Drug: Intrauterine device,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine device, sterilisation, or oral contraceptives
Study: 31533578
Drug: Contraceptive discontinuation
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive discontinuation